Cecilia Bergonzini
PhD candidate / guest
- Name
- C. Bergonzini MSc
- Telephone
- +31 71 527 4496
- c.bergonzini@lacdr.leidenuniv.nl
PhD candidate / guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Toxicology
- Bergonzini C., Gregori A., Hagens T.M.S., Noord V.E. van der, Water B. van de, Zweemer A.J.M., Coban B., Capula M., Mantini G., Botto A., Finamore F., Garajova I., McDonnell L.A., Schmidt T., Giovannetti E. & Danen E.H.J. (2024), ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells, Journal of Experimental & Clinical Cancer Research 43: 4.
- Che P.P., Gregori A., Bergonzini C., Ali M., Mantini G., Schmidt. T., Finamore F., Fraga Rodrigues S.M., Frampton A.E., McDonnell L.A., Danen E.H.J., Slotman B.J., Sminia P. & Giovannetti E. (2024), Differential sensitivity to ionizing radiation in gemcitabine- and paclitaxel-resistant pancreatic cancer cells, International Journal of Radiation Oncology - Biology - Physics 118(5): 1328-1343.
- Bergonzini C., Giovannetti E. & Danen E.H.J. (2024), Targeting ABC transporters in PDAC - past, present, or future?, OncoTarget 15: 403-406.
- Gregori A., Bergonzini C., Capula M., Mantini G., Khojasteh-Leylakoohi F., Comandatore A., Khalili-Tanha G., Khooei A., Morelli L., Avan A., Danen E.H., Schmidt T. & Giovannetti E. (2023), Prognostic significance of integrin subunit alpha 2 (ITGA2) and role of mechanical cues in resistance to gemcitabine in pancreatic ductal adenocarcinoma (PDAC), Cancers 15(3): 628.
- Bergonzini C., Kroese K., Zweemer J.M. & Danen E.H.J. (2022), Targeting integrins for cancer therapy - disappointments and opportunities, Frontiers in Cell and Developmental Biology 10: 863850.
- Coban B., Bergonzini C., Zweemer J.M. & Danen E.H.J. (2020), Metastasis: crosstalk between tissue mechanics and tumour cell plasticity, British Journal of Cancer 124(1): 49-57.